(Q35163712)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

relapsing-remitting multiple sclerosis

28 January 2020

main subject

multiple sclerosis

0 references

1 reference

Luiz Guilherme Stark Aroeira

inferred from title

author

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Exuperio Díez Tejedor

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Jaime Ramos-Cejudo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Celia Oreja-Guevara

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Luis Rodriguez de Antonio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Beatriz Chamorro

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

14 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Immunology

28 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

623-631

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10875-011-9522-x

28 January 2020

exact match

0 references

cites work

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3155864

Effects of natalizumab treatment on Foxp3+ T regulatory cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3155864

Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3155864

CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3155864

Natalizumab for multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3155864

Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3155864

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3155864

Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3155864

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3155864

Integrins as a primary signal transduction molecule regulating monocyte immediate-early gene induction

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3155864

Allergic and nonallergic delayed infusion reactions during natalizumab therapy

28 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-011-9522-X

CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-011-9522-X

Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-011-9522-X

Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-011-9522-X

IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-011-9522-X

Glatiramer acetate: mechanisms of action in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-011-9522-X

CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-011-9522-X

Suppressor T cells in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-011-9522-X

Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells

21 January 2018

1 reference

12 December 2020

Integrin engagement induces monocyte procoagulant activity and tumor necrosis factor production via induction of tyrosine phosphorylation

1 reference

12 December 2020

Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis

1 reference

12 December 2020

Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression

1 reference

12 December 2020

Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells

1 reference

12 December 2020

Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis

1 reference

12 December 2020

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

1 reference

12 December 2020

10.1007/S10875-011-9522-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21491095%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

PubMed publication ID

21491095

1 reference